Quad-Drug ACT Regimen for Drug-Resistant Malaria Relapse
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-malarial drugs face challenges in effectively treating all forms of malaria, particularly those caused by Plasmodium species, due to drug resistance, and fail to prevent relapse or reoccurrence without causing side effects, especially when administered in remote areas where diagnostic tools are limited.
Innovation Solution
A quad-therapy approach using artemether, artesunate, berberine, and primaquine, administered via sublingual spray and oral routes, targets parasites in the bloodstream, digestive tract, and liver to eliminate all forms of malaria without species-specific diagnosis, ensuring rapid action and preventing relapse.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-malarial drugs are used, then treatment of malaria is provided, but drug resistance develops and relapse occurs
Solution Approach 1:
The treatment is divided into multiple sequential stages using different drug compositions: first composition (artemisinin derivative) for rapid parasite clearance, second composition (antifolate agent) for preventing relapse by targeting liver stages, and third composition (antibacterial agent) for eliminating gut stages. This segmented approach ensures comprehensive coverage of all parasite life cycle stages without allowing resistance development.
Solution Approach 2:
The invention uses composite drug regimens combining multiple agents with different mechanisms of action: artemisinin derivatives (rapid killing), antifolate agents (relapse prevention), and antibacterial agents (gut stage elimination). This composite therapy approach addresses both current infection and prevents future relapses while minimizing resistance development through multi-target action.
2Measurement precision
If species-specific diagnosis is performed, then targeted treatment is provided, but diagnostic tools are unavailable in remote areas
Solution Approach 1:
The treatment protocol is designed to be universally effective against all Plasmodium species causing malaria (P. falciparum, P. vivax, P. ovale, P. malariae) without requiring species-specific diagnosis. The multi-component regimen addresses all life cycle stages common to all species, making it suitable for remote areas where diagnostic tools are unavailable while maintaining treatment effectiveness.
3Ease of operation
If single drug therapy is used, then treatment simplicity is maintained, but resistance develops quickly
Solution Approach 1:
The treatment is segmented into distinct phases with different drug compositions administered sequentially: first composition for acute phase, second composition for relapse prevention, and third composition for gut stage elimination. This segmentation maintains relative simplicity of administration while preventing resistance through multi-stage targeting.
Solution Approach 2:
Composite drug regimens combining multiple agents with different mechanisms of action are used: artemisinin derivatives (rapid killing), antifolate agents (relapse prevention), and antibacterial agents (gut stage elimination). This composite approach prevents resistance development through multi-target action while maintaining structured simplicity in administration protocol.
Data Source
AI summary
The present invention describes a method of treating individuals suffering from microbial infections, including a parasitic disease such as malaria, by using an improved Artemisinin Combination Therapy (ACT), known as ActRx Tri-ACT Plus. The improved ACT therapy includes administering a combination of four drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is administered to the individual. A fourth composition, an effective amount of primaquine, or its pharmaceutically acceptable derivatives or salts is administered to the individual.